Videos

Seth Miller, of Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

Anat Loewenstein, MD, MHA, explores dual Ang-2/VEGF-A inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium highlights and thoughts on current treatments options for DME and exudative AMD are discussed. 

Dr Anthony Khawaja, speaks on how ophthalmologists can revolutionise the diagnosis and treatment of glaucoma through precision management.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Emerging agents and therapies in the pipeline for the treatment of diabetic retinopathy and diabetic macular edema.

Challenges commonly faced by providers for the treatment of diabetes and how to ensure patients come back for follow-up visits.

The role of DRCR.net clinical trials in guiding the management of DR/DME and a review of the safety and efficacy of anti-VEGF agents.

Approaching the practical management of proliferative and nonproliferative diabetic retinopathy (DR) and diabetic macular edema (DME) according to the ADA (American Diabetes Association) guidelines.

Experts discuss successful communication among optometrists, retina specialists, and primary care providers when treating a patient with diabetes.

A discussion on educating a patient with diabetes on disease management, including routine hemoglobin A1C screenings to optimize health, and sending a referral to a retina specialist.

Evaluating the use of OCT-A for patients with diabetes in clinical practice and whether it should become a standard of care.

The importance of imaging in a diabetes eye exam with OCT-A and widefield angiograms is examined.

Expert optometrists and ophthalmologists provide an overview of diabetic retinopathy and the standard of care for a diabetes eye exam.

A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.

Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.

Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.

Cynthia Matossian, MD, FACS, ABES, presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.